Navigation Links
Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices
Date:9/29/2008

Company Finalizes Previously Announced Agreement with U.S. Attorney's Office for Eastern District of Pennsylvania and U.S. Department of Justice

Settles State Cases with Connecticut and Massachusetts

FRAZER, Pa., Sept. 29 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today it has finalized a previously announced agreement in principle with the U.S. Attorney's Office for the Eastern District of Pennsylvania, the U.S. Department of Justice and various other federal agencies. The Company also reached separate agreements with the Attorneys General of the states of Connecticut and Massachusetts to settle related investigations into the company's sales and promotional practices. The initial investigations began in 2004 and involved three of the company's nine proprietary products in the United States -- Actiq(R) (oral transmucosal fentanyl citrate) [C-II], Provigil(R) (modafinil) Tablets [C-IV], and GabitRil(R) (tiagabine hydrochloride). Cephalon fully cooperated with all governmental entities throughout these investigations.

Under the previously disclosed terms of the federal settlement, Cephalon will pay the $425 million reserved in 2007 plus an estimated $12 million in accrued interest expense, plead guilty to a single misdemeanor violation of the U. S. Food, Drug, and Cosmetic Act, and enter into a five-year Corporate Integrity Agreement (CIA) with the Office of the Inspector General of the U.S. Department of Health and Human Services. The guilty plea is subject to approval by the U.S. District Court for the Eastern District of Pennsylvania.

"We are pleased to have these long-standing matters behind us, while preserving our ability to participate in all federal and state health care programs, thereby maintaining the access of patients in those programs to our medications," stated Jerry Pappert, Executive Vice President and General Counsel, and a former Attorney General of the Commonwealth of Pennsylvania. '/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...ITHERSBURG, Md., Nov. 5 ...financial results for the third quarter ended Sept... million ($0.04 per share) for the three months en...6.8 million ($0.08 per share) in the comparable qu... 30, 2009, GenVec,s net loss was $14.1 million ($0...
(Date:11/5/2009)...N DIEGO, Nov. 5 Imagenet...ay that William Spencer, President and CEO of Imag...the 2nd annual LD MICRO Conference on Thursday, De...Los Angeles. ,, About LD MICRO ,, LD MICRO i...s on finding undervalued companies in the micro-ca...
(Date:11/5/2009)...AHA, Neb., Nov. 5 Transg...unced financial results for the quarter ended Sept...e presented in the tables that follow. ,, Thir...oss of $366,000 or $0.01 per share for the third q...00 or $0.01 per share for the third quarter of 200...
(Date:11/5/2009)...RT WORTH, Texas, Nov. 5 ...nced today that it has entered into a Letter of In...Virtual Health Technologies, Inc. (OTC Bulletin Bo...$1,000,000 in cash and debt, 4,000,000 shares of W... by WNDM on the Veriscrip technology being acquire...
Breaking Biology Technology:GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3
...New Flavor Ingredient Achieves ...ber 28, 2008 Senomyx,Inc. (Nasdaq: SNMX ), a lea...gies to discover and develop novel flavor ingredie...dustries, announced today that it has,received a p...ated to a,milestone achieved by Senomyx under the ...
...n Company,s Website -, TUSTIN, Calif., Oct. 28 P... clinical stage biopharmaceutical,company developi...er and,serious virus infections, today announced t...stor Forum 2008 on Thursday, October 30, 2008 at,3...eld at the Palace Hotel,in San Francisco., A live...
...patients with symptomatic Chronic,Obstructive Pulm...ta show reductions in moderate and severe exacerba...on for marketing authorisation in EU and US expect...ation in the US to be initiated, ZURICH, Switzerl...results from a preliminary analysis of four Phase ...
Other Biology Technology:SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY 2SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY 3Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008 2Nycomed's Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies 2Nycomed's Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies 3
(Date:11/5/2009)...ity have developed synthetic molecules capable of ...V-infected cells, as well as to prostate cancer ce...nal of the American Chemical Society , could lead .... , The molecules called "antibody-recruiting ...uiting molecule targeting prostate cancer" (ARM-P)...
(Date:11/4/2009)...tant to officially endorse green tea as a cancer p... its protective effects, including results of a ne... a journal of the American Association for Cancer ...ncer. , Vassiliki Papadimitrakopoulo, M.D., pro...ead and Neck Medical Oncology at the University of...
(Date:11/4/2009)...ng Beach and Riverside are responsible for a signi... and the true impact of air pollution and ship emi...ed, according to researchers at the University of ...ppears in an online edition of the American Journ...of all childhood asthma cases in Long Beach and si...
Breaking Biology News(10 mins):New synthetic molecules trigger immune response to HIV and prostate cancer 2Does green tea prevent cancer? Evidence continues to brew, but questions remain 2USC study finds big air pollution impacts on local communities 2Operation Rescue Announces Keep It Closed Campaign 53523 1Operation Rescue Announces Keep It Closed Campaign 53523 2TWO NEW KLRI PEER REVIEWED PUBLICATIONS 3A Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause 3B Growth Hormone May Increase Risk 4814 1TWO NEW KLRI PEER REVIEWED PUBLICATIONS 3A Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause 3B Growth Hormone May Increase Risk 4814 2TWO NEW KLRI PEER REVIEWED PUBLICATIONS 3A Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause 3B Growth Hormone May Increase Risk 4814 3Switch to digital mammography leads to increased cancer detection rates 53519 1
...cal rainforest interact with each other and their ...archers report in the Oct. 24 issue of the journal... forest dynamics plot of the Pontificia Universida...orest site associated with the Center for Tropical...th Observatory network (CTFS/SIGEO)., It is diffic...
... positive experience. However, by infecting the co... with a Salmonella strain known for causing human...ife Sciences at Arizona State University have shed... broad implications for understanding embryonic de... in humans. Associate Professor Stuart Newfeld and...
...to the mechanisms that underlie a pathological inc...ished by Cell Press in the October 24th issue of t...opment of new strategies for managing this extreme...t failure. , High blood pressure, heart valve dis...kening of the heart muscle, called myocardial hype...
Other Biology News:Diversity of trees in Ecuador's Amazon rainforest defies simple explanation 2Making flies sick reveals new role for growth factors in immunity 2Making flies sick reveals new role for growth factors in immunity 3Making flies sick reveals new role for growth factors in immunity 4Research uncovers new steps on pathway to enlarged heart 2
...urce: Calf thymus Description: Topoisomerase I r...DNA by a transient breakage and rejoining of phosp...ith Topoisomerase I allows molecules to be differe...phoresis (3) . Topoisomerase I is active in the ab...
...A Polymerase I catalyzes the template-directed pol...3 direction. DNA Polymerase I possesses a 3?5 exon... lowers the error rate during DNA replication, and...nables the enzyme to replace nucleotides in the gr...
T7 RNA Polymerase from Invitrogen
T7 RNA Polymerase from Roche Applied Science
Biology Products: